Article

Dr. Madhav Dhodapkar on IMiD-based Combinations in Multiple Myeloma

Madhav Dhodapkar, MBBS, clinical research program leader in the Hematology Program at Yale Cancer Center, discusses the changing role of immunomodulatory drugs (IMiDs) in multiple myeloma.

IMiDs have clear immunologic effects, says Dhodapka. IMiD-based combinations offer a lot of potential. There is emerging data on combination checkpoint inhibitors with IMiDs which looks very promising. There is already data showing efficacy between IMiDs and monocolonal antibodies, another immune-targeting agent, says Dhodapka.

The ideal combinations may dependent on the individual patient, as each patient has a unique immune microenvironment. Immune-based combinations may need to be personalized based on molecular profiling, says Dhodapka.

Related Videos
Funda Meric-Bernstam, MD
Bhavana Pothuri, MD
Kristen Spencer, DO
Laurence Albigès, MD, PhD
Nirav Shah, MD, MSHP, discusses evaluating zamtocabtagene autoleucel in patients with relapsed/refractory diffuse large B-cell lymphoma.
Bhagirathbhai Dholaria, MBBS
Sairah Ahmed, M.D
Joshua K. Sabari, MD
Barry W. Goy, MD
Fred Saad, CQ, MD, FRCS, FCAHS, director, Prostate Cancer Research, Montreal Cancer Institute, Centre Hospitalier de l’Université de Montréal; full professor, Department of Surgery, Université de Montréal; uro-oncologist, Urology Department, University of Montreal Health Center